# To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

> **NCT00050648** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rockefeller University** · enrollment: 20 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Daclizumab
- **DRUG:** Cyclosporine
- **DRUG:** cyclosporine and Daclizumab

## Key facts

- **NCT ID:** NCT00050648
- **Lead sponsor:** Rockefeller University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2004-09
- **Final completion:** 2008-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2009-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050648, "To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00050648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*